KZE has prepared a broad array of medical, regulatory, and strategic communication products in support of drugs developed for the treatment of asthma, COPD, influenza, secondary infections in patients with chronic bronchitis and sinusitis, and sepsis in patients with community-acquired pneumonia.
Medical Writing Products
Peer reviewed clinical trial-based manuscripts
Health outcomes and pharmacoeconomic manuscripts
Publication planning for a selective phosphodiesterase 4 Inhibitor for COPD
Publication planning for products for treating influenza, sinusitis, and chronic bronchitis
Safety review of salmeterol use in pediatric asthma patients
-Clinical and economical value of dual-controller therapy in asthma management
-Value in using asthma economic outcomes data in disease decision making
-A decision analytic economic evaluation of first-line controller therapies for persistent asthma
Bibliography: Sample Publications and Abstracts
EO Meltzer, C Andrews, GE Journeay et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol 104(4):331-8, 2010.
P-F Laterre, SM Opal, E Abraham, SP et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Critical Care 2009, 13:R36 2009.
EO Meltzer, J Stahlman, J Leflein, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone paropionate nasal sprays: A randomized, multicenter, double-blind, single-dose, croosover study. Clin Ther 30: 1-9, 2008.
AL Levy, JT Given, SF Weinstein, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in four- to eleven-year-old children with asthma: a randomized, double-blinded, placebo-controlled study. Pediatric Asthma, Allergy & Immunology 19 (2): 106 -117, 2006.
PY Qagundah, RW Sugarman, E Ceruti, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre–school-age children with asthma: A randomized, double-blind, placebo-controlled study J Pediatrics 149, (5): 663-670, 2006.
A Peng, S Milleri, DS Stein. Direct measurement of the anti-influenza compound zanamivir in the respiratory tract following inhaled administration. Antimic Agents Chemother, 44: 1974-76, 2000
A Peng, EK Hussey, KHP Moore. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza J Clin Pharm, 40:242-49, 1999
CA DeAbate, D Myers, D Henry, et al. Comparative efficacy and tolerability of once-daily grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Drug Investigation, 17(1):21-31, 1999.
DC Henry, GE Ruoff, M Noonan, et al. Comparative efficacy and tolerability of short-course (5-days) cefuroxime axetil with amoxicillin/clavulanate (10-days) in the treatment of secondary bacterial infections of acute bronchitis Clin Drug Invest, 1999.
CE Langan, F Zuck, A Vogel, et al. Comparative efficacy and safety of short-course (five-day) grepafloxacin versus ten-day clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. J Antimic Chemother, 1999.
SH Randell, JY Liu, PC Ferriola, et al. Regulation of mucin production in SPOC1 cells: an airway epithelial mucous goblet cell line. Am. J. Resp. Cell Mol. Biol. 14:146-154, 1996.
Ferriola, PC, Ambroso, JL, Patrone, LM, Stedman, DB and Welsch, F.: Localizing and quantifying toxicological responses in lung cells with confocal laser scanning microscopy. CIIT Activities 16(6): 1-8, 1996.
MM Doherty, JY Liu, et al., and Ferriola, P.C.: Phenotype and differentiation potential of a novel airway epithelial cell line. Am. J. Resp. Cell Mol. Biol. 12:385-95, 1995.
EM Middleton, PC Ferriola, G Drzewiecki, and RD Sophia. The effect of azelastine and other anti-asthmatic and anti-allergy drugs on calmodulin and protein kinase C. Agents and Actions, 28:9-15, 1989.
EM Middleton and PC Ferriola. Effect of flavonoids on PKC: relationship to inhibition of human basophil histamine release. In: Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular and Medicinal Properties, EM Middleton, V Cody and J Harborne, eds., New York: Alan R. Liss, Inc., 1988.
EM Middleton and PC Ferriola. Effect of flavonoids on protein kinase C: relationship to inhibition of human basophil histamine release. Prog Clin Biol Res 280: 251-66, 1988.